Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-23 00:54 | 2025-10-21 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $424.96 | 8,000 | $3,399,650 | 130 |
| 2025-10-22 00:43 | 2025-10-20 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Director, Officer | BUY | $13.64 | 20,000 | $272,790 | 468,277 |
| 2025-10-22 01:13 | 2025-10-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $21.33 | 12,500 | $266,654 | 902,892 |
| 2025-10-21 23:54 | 2025-10-20 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Altmeyer Anne | Director | OPT+S | $20.50 | 1,060 | $21,730 | 6,191 |
| 2025-10-22 00:12 | 2025-10-21 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Director | SELL | $34.22 | 88,878 | $3,041,681 | 686,567 |
| 2025-10-21 19:24 | 2025-10-20 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $4.97 | 6,500 | $32,287 | 0 |
| 2025-10-21 23:30 | 2025-10-20 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $427.41 | 22,500 | $9,616,703 | 0 |
| 2025-10-22 00:30 | 2025-10-17 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.37 | 16,775 | $677,198 | 23,899 |
| 2025-10-22 01:18 | 2025-10-21 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $58.22 | 2,105 | $122,553 | 140,610 |
| 2025-10-20 23:11 | 2025-10-16 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | Director, Officer | OPT+S | $18.83 | 24,103 | $453,761 | 309,892 |
| 2025-10-20 23:30 | 2025-10-16 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Shulman Joseph | Officer | OPT+S | $112.03 | 14,437 | $1,617,337 | 8,509 |
| 2025-10-20 23:44 | 2025-10-17 | MBX | MBX Biosciences, Inc. | Hoerter Steven L. | Director | BUY | $13.25 | 20,000 | $264,984 | 20,000 |
| 2025-10-21 03:00 | 2025-10-16 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.73 | 131,311 | $227,680 | 1,518,893 |
| 2025-10-21 04:39 | 2025-10-16 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Director | SELL | $32.30 | 286,369 | $9,251,093 | 701,985 |
| 2025-10-20 23:12 | 2025-10-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | Officer | SELL | $2.62 | 1,248 | $3,275 | 392,422 |
| 2025-10-20 16:11 | 2025-10-17 | GOVX | GeoVax Labs, Inc. | SPENCER JOHN N JR | Director | BUY | $0.55 | 10,000 | $5,498 | 21,402 |
| 2025-10-21 02:13 | 2025-10-17 | JNJ | JOHNSON & JOHNSON | REED JOHN C | Officer | OPT+S | $192.71 | 21,721 | $4,185,793 | 10,658 |
| 2025-10-21 01:00 | 2025-10-15 | BGMS | Bio Green Med Solution, Inc. | Kua Khai Loon | 10% owner | SELL | $4.33 | 95,683 | $414,298 | 242,477 |
| 2025-10-21 01:00 | 2025-10-16 | BGMS | Bio Green Med Solution, Inc. | FITTERS Diversified Berhad | 10% owner | SELL | $5.50 | 26,051 | $143,281 | 479,707 |
| 2025-10-20 14:15 | 2025-10-16 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $431.50 | 11,000 | $4,746,495 | 36,781 |
| 2025-10-20 23:31 | 2025-10-17 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $427.63 | 8,000 | $3,421,037 | 130 |
| 2025-10-17 23:32 | 2025-10-16 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $90.63 | 27,000 | $2,447,021 | 249,062 |
| 2025-10-17 23:32 | 2025-10-15 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $90.72 | 28,000 | $2,540,289 | 49,086 |
| 2025-10-17 23:31 | 2025-10-15 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Officer | OPT+S | $90.04 | 14,205 | $1,279,018 | 65,963 |
| 2025-10-17 23:31 | 2025-10-15 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $85.57 | 1,683 | $144,014 | 61,734 |
| 2025-10-18 00:11 | 2025-10-15 | SION | Sionna Therapeutics, Inc. | Cloonan Michael | Director, Officer | OPT+S | $31.28 | 25,200 | $788,153 | 547,343 |
| 2025-10-18 04:00 | 2025-10-15 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $16.99 | 851,383 | $14,467,466 | 1,504,959 |
| 2025-10-17 23:27 | 2025-10-15 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | Officer | OPT+S | $50.15 | 20,000 | $1,003,058 | 97,130 |
| 2025-10-17 23:41 | 2025-10-15 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Director | SELL | $85.97 | 93,585 | $8,045,250 | 385,549 |
| 2025-10-18 00:53 | 2025-10-15 | KROS | Keros Therapeutics, Inc. | Pontifax Management 4 G.P. (2015) Ltd. | 10% owner | SELL | $17.75 | 4,787,331 | $84,975,125 | 0 |
| 2025-10-17 23:15 | 2025-10-16 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $25.22 | 5,000 | $126,100 | 113,730 |
| 2025-10-17 23:28 | 2025-10-16 | SDGR | Schrodinger, Inc. | Dugan Margaret | Officer | SELL | $21.07 | 1,395 | $29,387 | 24,574 |
| 2025-10-17 23:10 | 2025-10-16 | PRAX | Praxis Precision Medicines, Inc. | Adage Capital Management, L.P. | 10% owner | SELL | $105.76 | 313,910 | $33,198,117 | 2,060,175 |
| 2025-10-17 21:01 | 2025-10-15 | AQST | Aquestive Therapeutics Inc. | Jung Cassie | Officer | OPT+S | $7.01 | 67,575 | $473,701 | 240,771 |
| 2025-10-17 21:01 | 2025-10-15 | AQST | Aquestive Therapeutics Inc. | Kraus Carl N | Officer | SELL | $7.00 | 20,272 | $141,904 | 282,475 |
| 2025-10-17 21:00 | 2025-10-15 | AQST | Aquestive Therapeutics Inc. | Boyd Peter E. | Officer | SELL | $7.00 | 10,000 | $70,000 | 268,323 |
| 2025-10-17 03:16 | 2025-10-15 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer | OPT+S | $73.06 | 7,263 | $530,638 | 17,494 |
| 2025-10-16 23:41 | 2025-10-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | OPT+S | $18.16 | 12,500 | $226,943 | 198,141 |
| 2025-10-16 23:30 | 2025-10-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $25.79 | 8,500 | $219,196 | 409,642 |
| 2025-10-17 03:15 | 2025-10-14 | IONS | IONIS PHARMACEUTICALS INC | Birchler Brian | Officer | OPT+S | $72.13 | 23,900 | $1,723,988 | 56,826 |
| 2025-10-16 23:15 | 2025-10-16 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | Director, Officer | SELL | $5.49 | 249 | $1,366 | 1,189,818 |
| 2025-10-16 23:13 | 2025-10-15 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $22.41 | 6,000 | $134,439 | 105,386 |
| 2025-10-17 03:16 | 2025-10-16 | IONS | IONIS PHARMACEUTICALS INC | Swayze Eric | Officer | OPT+S | $73.62 | 53 | $3,902 | 256 |
| 2025-10-16 23:35 | 2025-10-14 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $37.67 | 12,368 | $465,843 | 28,684 |
| 2025-10-16 23:30 | 2025-10-15 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | Director, Officer | SELL | $25.81 | 10,916 | $281,729 | 41,061 |
| 2025-10-16 23:21 | 2025-10-07 | EBS | Emergent BioSolutions Inc. | Glessner Coleen | Officer | SELL | $10.00 | 30,608 | $306,080 | 144,319 |
| 2025-10-16 23:01 | 2025-10-14 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $3.96 | 28,918 | $114,582 | 67,006 |
| 2025-10-17 01:00 | 2025-10-14 | BGMS | Bio Green Med Solution, Inc. | Ong Yee Lung | 10% owner | SELL | $6.00 | 135,793 | $814,758 | 268,672 |
| 2025-10-16 23:30 | 2025-10-15 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $433.30 | 8,000 | $3,466,417 | 130 |
| 2025-10-17 03:16 | 2025-10-15 | IONS | IONIS PHARMACEUTICALS INC | PARSHALL B LYNNE | Director | SELL | $71.74 | 5,000 | $358,722 | 61,344 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.